Background:Despite highly effective vaccines against SARS-CoV-2,COVID-19 vaccine hesitancy persisted in some populations in England during the pandemic,with rates and motivations for hesitancy varying by demographic g...Background:Despite highly effective vaccines against SARS-CoV-2,COVID-19 vaccine hesitancy persisted in some populations in England during the pandemic,with rates and motivations for hesitancy varying by demographic group.Addressing the drivers of vaccine hesitancy through targeted interventions in hesitant groups is a public health priority for better and more rapid control of disease spread.We aimed to characterise the determinants and subtypes of vaccine hesitancy and identify more persistent forms of hesitancy via analysis of vaccine uptake in a large cross-sectional cohort with linked National Health Service(NHS)data.展开更多
The global burden of bacterial infections,exacerbated by antimicrobial resistance(AMR),necessitates innovative strategies.Bacterial protein vaccines offer promise by eliciting targeted immunity while circumventing AMR...The global burden of bacterial infections,exacerbated by antimicrobial resistance(AMR),necessitates innovative strategies.Bacterial protein vaccines offer promise by eliciting targeted immunity while circumventing AMR.However,their clinical translation is hindered by their inherently low immunogenicity,often requiring potent adjuvants and advanced delivery systems.Biomembrane nanostructures(e.g.,liposomes,exosomes,and cell membrane-derived nanostructures),characterized by superior biocompatibility,intrinsic targeting ability,and immune-modulating properties,could serve as versatile platforms that potentiate vaccine efficacy by increasing antigen stability,enabling codelivery of immunostimulants,and facilitating targeted delivery to lymphoid tissues/antigen-presenting cells.This intrinsic immunomodulation promotes robust humoral and cellular immune responses to combat bacteria.This review critically reviews(1)key biomembrane nanostructure classes for bacterial protein antigens,(2)design strategies leveraging biomembrane nanostructures to enhance humoral and cellular immune responses,(3)preclinical efficacy against diverse pathogens,and(4)translational challenges and prospects.Biomembrane nanostructure-driven approaches represent a paradigm shift in the development of next-generation bacterial protein vaccines against resistant infections.展开更多
Malignant melanoma,characterized by its high metastatic potential and resistance to conventional therapies,presents a major challenge in oncology.This review explores the current status and advancements in tumor vacci...Malignant melanoma,characterized by its high metastatic potential and resistance to conventional therapies,presents a major challenge in oncology.This review explores the current status and advancements in tumor vaccines for melanoma,focusing on peptide,DNA/RNA,dendritic cell,tumor cell,and neoantigen-based vaccines.Despite promising results,significant challenges remain,including the immunosuppressive tumor microenvironment,patient heterogeneity,and the need for more effective antigen presentation.Recent strategies,such as combining vaccines with immune checkpoint inhibitors(ICIs),aim to counteract immune evasion and enhance T cell responses.Emerging approaches,including personalized neoantigen vaccines and the use of self-amplifying RNA platforms,hold promise for overcoming tumor heterogeneity and improving vaccine efficacy.Additionally,optimizing vaccine delivery systems through nanotechnology and genetic modifications is essential for increasing stability and scalability.This review highlights the potential of these innovative strategies to address current limitations,with a focus on how future research can refine and combine these approaches to improve melanoma treatment outcomes.展开更多
Objective:To evaluate the cost-effectiveness of annual trivalent inactivated influenza vaccine(IIV3)under the context of Zhejiang province.Methods:A state transition simulation model was constructed to estimate the he...Objective:To evaluate the cost-effectiveness of annual trivalent inactivated influenza vaccine(IIV3)under the context of Zhejiang province.Methods:A state transition simulation model was constructed to estimate the health and economic outcomes of IIV3 vaccination program compared to no vaccination for hypothetical cohorts of Zhejiang province stratified by age and risk status.Model input parameters were chosen based on published literatures and expert advices.The analysis used societal perspectives and a one-year time horizon,and permanent outcomes were also included.The primary outcome was the incremental cost-effectiveness ratio(ICER),with expression of US dollars per quality adjusted life years(QALYs)gained.Results:In subgroups not at high risk for influenza-related complications(non-high risk subgroup),ICER ranged from $6268/QALY(for adults aged 50-64 years)to $11260/QALY(for children aged from 6 months to 4 years).In subgroups at high risk for influenza-related complications(high risk subgroup),ICER ranged from cost-saving(adults aged≥65 years)to $5260/QALY(for children aged from 6 months to 4 years).ICER were most sensitive to changes in probability of influenza illness,cost of hospitalization,and probability of death for adults aged 18-49 years with non-high risk status.Conclusions:ICERs of annual influenza vaccination varied by age and risk status but were less than the Gross Domestic Product(GDP)per capita of Zhejiang province($17745 in 2023),which remained cost-effective for all-age and different risk status groups from a societal perspective.展开更多
BACKGROUND Patients with inflammatory bowel diseases(IBD)often miss the scheduled vaccines and have a higher risk of infection susceptibility,including vaccineprevented diseases.AIM To evaluate the vaccine coverage an...BACKGROUND Patients with inflammatory bowel diseases(IBD)often miss the scheduled vaccines and have a higher risk of infection susceptibility,including vaccineprevented diseases.AIM To evaluate the vaccine coverage and levels of the post-vaccine antibodies against measles,mumps,rubella,and hepatitis B in children with IBD.METHODS Total 98 patients:46 females(47.2%)and 52 males(52.8%)with IBD(Crohn’s disease-75%and ulcerative colitis-25%)with disease onset age-11.0(6.0;14.0)years whom clinical data,vaccination status and levels of the postvaccination antibodies(IgG)for measles,rubella,mumps,hepatitis B,measured with ELISA were prospectively evaluated.The control group consisted of 88 healthy peers from the biobank data.RESULTS Patients with IBD had lower levels of measles,rubella,and hepatitis B,except mumps,compared to controls.Incomplete vaccination/non-protective titer of the antibodies against measles,mumps rubella,and hepatitis B had 33(33.7%)/52.3%,21(21.4%)/50.4%,26(25.8)/25.6%and 26(25.8%)/55.2%,respectively.Patients with incomplete vaccination had a lower age at the diagnosis for all vaccines.The age of the IBD diagnosis≤6 years was the predictor of incomplete vaccination for measles[odds ratio(OR)=4.6,P=0.001],mumps(OR=5.0,P=0.001),rubella(OR=5.4,P=0.0005)and hepatitis B(OR=5.4,P=0.0005)and corticosteroid treatment for measles(OR=2.2,P=0.074)and mumps(OR=3.0,P=0.047)vaccines.Incomplete vaccination was the predictor of nonprotective titer of antibodies against rubella(OR=6.8,95%CI:2.3-19.9,P=0.0002)/mumps(OR=7.0,95%CI:2.4-20.8;P=0.0002).CONCLUSION Patients with IBD had low vaccine coverage and lower levels of anti-vaccine antibodies against measles,rubella,and hepatitis B.Nearly half of the IBD patients require revaccination.展开更多
Dear Editor,Influenza viruses cause significant mortality and morbidity in humans.Vaccination is currently the most effective way to combat the virus(Perofsky and Nelson,2020).Unfortunately,the influenza virus frequen...Dear Editor,Influenza viruses cause significant mortality and morbidity in humans.Vaccination is currently the most effective way to combat the virus(Perofsky and Nelson,2020).Unfortunately,the influenza virus frequently changes its antigenicity through rapid mutations,leading to decreased vaccine efficacy or even failure.To improve vaccine effectiveness,it is necessary to monitor antigenic variation and update vaccine strains when significant antigenic variation occurs(Perofsky and Nelson,2020;Malik et al.,2024).展开更多
Minks are highly susceptible to SARS-CoV-2,and have transmitted SARS-CoV-2 to humans.Oral immunization is one of the most promising strategies to prevent SARS-CoV-2 infection and transmission in minks.Here,we generate...Minks are highly susceptible to SARS-CoV-2,and have transmitted SARS-CoV-2 to humans.Oral immunization is one of the most promising strategies to prevent SARS-CoV-2 infection and transmission in minks.Here,we generated 3 recombinant rabies viruses(RABV),rERAG_(333E)/S6P,rERAG_(333E)/DS6P and rERAG_(333E)/BA2S6P,expressing the prefusion-stabilized SARS-CoV-2 spike protein of wild-type(S6P),δ(DS6P)or BA.2(BA2S6P)strain based on an oral rabies vaccine candidate(rERAG_(333E)).Oral or inactivated immunization of the 3 RABVs monovalent or trivalent were safe,and induced robust RABV neutralizing antibody and cross-antibody responses against the three SARS-CoV-2 in mice and minks.The challenge tests showed that 2 doses of rERAG_(333E)-S6P as an oral or inactivated vaccine completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts,and largely prevented viral replication and lung damage caused by wild-type SARS-CoV-2infection in minks.Notably,we also confirmed that 2 doses of rERAG_(333E)-S6P as an oral or inactivated vaccine can largely protect minks against wild-type SARS-CoV-2 transmission via respiratory droplets.Our findings suggest that rERAG_(333E)-based COVID-19 vaccines appear to be suitable oral candidates to protect minks from SARS-CoV-2infection and transmission,and may serve as inactivated vaccines for further investigation in humans.展开更多
Most vaccines get injected into muscle,swallowed by mouth,or squirted into the nose.But in a clinical study reported in January 2025 in Nature Medicine[1],researchers in the Netherlands used a less conventional method...Most vaccines get injected into muscle,swallowed by mouth,or squirted into the nose.But in a clinical study reported in January 2025 in Nature Medicine[1],researchers in the Netherlands used a less conventional method to deliver an investigational vaccine:mosquito bites.The mosquitoes carried malaria-causing Plasmod-ium falciparum parasites that had been genetically engineered to trigger a productive immune response without making people sick.Nine of ten study participants who each,in a single session,with-stood 50 bites from this laboratory strain of mosquitoes,success-fully fended off infection when challenged with infective malaria parasites six weeks later.展开更多
Background:Vaccine hesitancy remains a pressing global challenge,impacting the acceptance and distribution of both long-established and newly developed vaccines.This paper investigates the multifaceted nature of vacci...Background:Vaccine hesitancy remains a pressing global challenge,impacting the acceptance and distribution of both long-established and newly developed vaccines.This paper investigates the multifaceted nature of vaccine hesitancy,focusing on the development of the measles vaccine as a historical case study,while drawing comparisons to the coronavirus disease 2019(COVID-19)pandemic.Methods:The study employs a historical and comparative approach to analyze vaccine hesitancy.It examines how technological advances,public policy,and communication strategies have influenced vaccine acceptance.Key lessons from the development of the measles vaccine are compared with challenges encountered during the rapid development and deployment of COVID-19 vaccines.Results:Both historical and contemporary examples reveal commonalities and differences in addressing vaccine hesitancy.While the measles vaccine demonstrated the importance of long-term safety evaluations and public trust-building,the COVID-19 vaccine highlighted the challenges of rapid development timelines and combating misinformation in a digital age.The findings underscore the necessity of transparent communication,equitable access,and proactive engagement in overcoming hesitancy.Conclusion:Understanding the historical and contemporary dynamics of vaccine hesitancy is crucial for promoting public trust and equitable vaccination in an evolving global health landscape.Effective strategies,combining historical lessons with modern innovations,can address public concerns and enhance vaccine acceptance.展开更多
Current treatments for chronic hepatitis B(CHB)are lifelong,often accompanied by side effects and the risk of drug resistance,highlighting the urgent need for alternative therapies such as therapeutic vaccines.However...Current treatments for chronic hepatitis B(CHB)are lifelong,often accompanied by side effects and the risk of drug resistance,highlighting the urgent need for alternative therapies such as therapeutic vaccines.However,challenges such as selecting appropriate antigens and addressing multiple hepatitis B virus(HBV)genotypes hinder the development of these vaccines.One approach to overcoming these challenges is reverse vaccinology(RV)combined with immunoinformatics.RV uses computational methods to identify antigens from pathogen genetic information,including genomic and proteomic data.These methods have helped researchers identify conserved epitopes across bacterial strains or viral species,including multiple HBV genotypes.Computational tools,such as epitope mapping algorithms,molecular docking analysis,molecular dynamics simulations,and immune response simulations,enable key epitope identification,predict vaccine candidates'binding potential to immune cell receptors,and forecast the immune response.Together,these approaches streamline therapeutic vaccine design for CHB,making it faster,more cost-effective,and accurate.This review aims to explore the potential role of RV and immunoinformatics in advancing therapeutic vaccine design for CHB.展开更多
Tuberculosis(TB)remains a critical global health challenge,with 10.8 million new cases and over 1.25 million deaths reported annually,disproportionately affecting low-income regions.Despite its use,the Bacillus Calmet...Tuberculosis(TB)remains a critical global health challenge,with 10.8 million new cases and over 1.25 million deaths reported annually,disproportionately affecting low-income regions.Despite its use,the Bacillus Calmette-Guérin(BCG)vaccine provides limited protection against adult pulmonary TB,necessitating novel solutions.The messenger RNA(mRNA)vaccine technology,proven effective in combating coronavirus disease 2019,offers significant promise for TB prevention.These vaccines elicit robust immune responses by encoding antigens that stimulate humoral and cell-mediated immunity,essential for combating mycobacterium TB.Unlike traditional methods,mRNA vaccines are highly adaptable,scalable,and capable of targeting emerging strains.Preclinical studies highlight the enhanced efficacy of mRNA TB vaccines over BCG,demonstrating their ability to reduce bacterial burdens and generate memory T-cell responses critical for long-term protection.However,challenges persist,including mRNA instability,cold-chain storage needs,and mycobacterium’s complex immune evasion strategies.Innovative solutions,such as lipid nanoparticle delivery systems and selfamplifying mRNA platforms,are being developed to address these barriers.The initiation of clinical trials,notably BioNTech’s BNT164,marks a pivotal advancement in TB vaccine development.These trials focus on safety,immuno genicity,and efficacy,particularly in regions with high TB prevalence.While logistical and financial hurdles remain,mRNA vaccines hold transformative potential to bridge critical gaps in TB prevention.Their adaptability extends to tackling co-infections like human immunodeficiency virus,further amplifying their impact on global health.By integrating mRNA vaccines into existing TB control strategies,these advancements could revolutionize prevention efforts,especially in regions where current solutions fall short.Continued innovation and investment are crucial to harnessing the full potential of mRNA vaccines,positioning them as a cornerstone in the fight against TB and its global eradication.展开更多
Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently follow...Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently followed by a significant rise in domestic infections commencing from June 2023.This alarming trend has escalated the likelihood of localized outbreaks and covert transmission,posing a heightened risk to public health.Notably,the United States,many European countries,and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure,based on their cross-protection efficacy.In recent years,virology research has broadened its scope to include investigations into various novel vaccine approaches,such as nucleic acid-based vaccines,protein subunit vaccines,and epitope peptide vaccines,and other related methodologies.This review offers a thorough examination of the current global landscape of Mpox prevalence,delves into the advancements in Mpox vaccine development,and highlights the progress achieved in Mpox vaccine research,serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.展开更多
Objective The objective of our study was to evaluate the vaccine effectiveness(VE)of the pentavalent rotavirus vaccine(RV5)among<5-year-old children in three provinces of China during 2020-2024 via a propensity sco...Objective The objective of our study was to evaluate the vaccine effectiveness(VE)of the pentavalent rotavirus vaccine(RV5)among<5-year-old children in three provinces of China during 2020-2024 via a propensity score-matched test-negative case-control study.Methods Electronic health records and immunization information systems were used to obtain data on acute gastroenteritis(AGE)cases tested for rotavirus(RV)infection.RV-positive cases were propensity score matched with RV-negative controls for age,visit month,and province.Results The study included 27,472 children with AGE aged 8 weeks to 4 years at the time of AGE diagnosis;7.98%(2,192)were RV-positive.The VE(95%confidence interval,CI)of 1-2 and 3 doses of RV5 against any medically attended RV infection(inpatient or outpatient)was 57.6%(39.8%,70.2%)and 67.2%(60.3%,72.9%),respectively.Among children who received the 3rd dose before turning 5 months of age,3-dose VE decreased from 70.4%(53.9%,81.1%)(<5 months since the 3rd dose)to 63.0%(49.1%,73.0%)(≥1 year since the 3rd dose).The three-dose VE rate was 69.4%(41.3%,84.0%)for RVGE hospitalization and 57.5%(38.9%,70.5%)for outpatient-only medically attended RVGE.Conclusion Three-dose RV5 VE against rotavirus gastroenteritis(RVGE)in children aged<5 years was higher than 1-2-dose VE.Three-dose VE decreased with time since the 3rd dose in children who received the 3rd dose before turning five months of age,but remained above 60%for at least one year.VE was higher for RVGE hospitalizations than for medically attended outpatient visits.展开更多
The original version of Figure 2 contained the following inaccuracies:Rotarix was incorrectly shown as a 3-dose vaccine instead of a 2-dose vaccine;RotaTeq and Rotasiil were incorrectly shown as 2-dose vaccines instea...The original version of Figure 2 contained the following inaccuracies:Rotarix was incorrectly shown as a 3-dose vaccine instead of a 2-dose vaccine;RotaTeq and Rotasiil were incorrectly shown as 2-dose vaccines instead of 3-dose vaccines;Polyvac was incorrectly shown as a 3-dose vaccine instead of a 2-dose regimen;and the LLR vaccine should have been indicated as a single primary dose followed by annual boosters between 2 months and 3 years of age.展开更多
Imagine a future where a single vaccine could protect you from a multitude of influenza strains,offering broad immunity with minimal risk.This vision is now closer to reality,thanks to a recent study that harnesses th...Imagine a future where a single vaccine could protect you from a multitude of influenza strains,offering broad immunity with minimal risk.This vision is now closer to reality,thanks to a recent study that harnesses the power of cellular proteins to create a new generation of live attenuated vaccines that outsmart flu’s relentless mutations.展开更多
BACKGROUND Child vaccination plays a great role in preventing infectious diseases in children.While Ethiopia has emphasized child vaccination,its effectiveness largely depends on efficient communication between health...BACKGROUND Child vaccination plays a great role in preventing infectious diseases in children.While Ethiopia has emphasized child vaccination,its effectiveness largely depends on efficient communication between health practitioners and mothers/caregivers.Thus,sufficient communication contributes to promoting child immunization and in turn improving child health.AIM To examine child vaccine communication practices and strategies as well as their relationship with sociodemographic characteristics of respondents in the Amhara region of Ethiopia.METHODS A quantitative cross-sectional survey was conducted using a pretested Likert scale questionnaire and distributed to 123 health workers in primary healthcare centers between April 2024 and June 2024.The data were analyzed using both descriptive and inferential statistics.RESULTS The results indicated that the most common vaccine communication activities included education and communication(mean score=24.1),vaccine data registration(mean score=8.86),and information exchange(mean score=8.3).A significant correlation was found between the implementation of interpersonal health communication principles and immunization communication training(F=341.756,P=0.000,P<0.05).However,no significant correlations were observed between age,education,work experience,and vaccine communication practices.Additionally,the study found that the application of interpersonal communication principles was associated with the perceived relevance of immunization communication(F=27.790,P=0.000,P<0.05).CONCLUSION Based on the findings the study concluded that communication practice in promoting child immunization is insufficient.To enhance vaccine acceptance,continuous immunization communication training for health workers is recommended.展开更多
Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific m...Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific mutations,particu-larly in the form of tumor neoantigens,to induce immune responses,particularly the activation of CD8+T cells,which can attack malignant cells.Since tumor mutations result in protein sequence alterations distinct from those in normal tissues,therapies that precisely target these alterations could,in principle,confer effective tumor control while minimizing off-target effects.展开更多
Bacckground:Based on the 3C model,this study explores the current situation of HPV vaccine hesitancy among women of childbearing age and the factors influencing vaccine hesitancy.Methods:Based on the free cervical can...Bacckground:Based on the 3C model,this study explores the current situation of HPV vaccine hesitancy among women of childbearing age and the factors influencing vaccine hesitancy.Methods:Based on the free cervical cancer screening project in Baoan District,this study designed a questionnaire under the framework of vaccine hesitation 3C theory and carried out a self-filling electronic questionnaire survey among women of childbearing age.Results:The rate of HPV vaccination awareness among women of childbearing age in Bao’an District was 93.25%.HPV vaccine acceptance reached 71.55%,and 24.59%of the survey respondents experienced HPV vaccine hesitation,a high percentage of whom were hesitant.The influencing factors of HPV vaccine hesitation among women of childbearing age were perceived necessity of HPV vaccination(0.482),no one around them receiving the HPV vaccine(0.411),perception of the price of the vaccine(0.354),degree of trust in the safety of the vaccine(0.223),and degree of concern about the HPV vaccine(0.153).Conclusion:The 3C model can be used for the study of HPV vaccine hesitancy.Strengthening the publicity of HPV vaccination and improving women’s knowledge of the HPV vaccine can reduce their hesitation toward HPV vaccination.展开更多
BACKGROUND Children with juvenile idiopathic arthritis(JIA)and inflammatory bowel disease(IBD)face an elevated risk of severe infection owing to their diseases and the immunosuppressive treatment for disease control.A...BACKGROUND Children with juvenile idiopathic arthritis(JIA)and inflammatory bowel disease(IBD)face an elevated risk of severe infection owing to their diseases and the immunosuppressive treatment for disease control.AIM To compare scheduled vaccination coverage and the levels of post-vaccine antibodies against measles,mumps,rubella(MMR)and hepatitis B in pediatric patients with IBD and JIA.METHODS A comparative cohort study included 97 patients with IBD and 170 patients with JIA.Vaccination history was obtained from medical records,while post-vaccination immunity was assessed prospectively by measuring specific IgG antibody titers using enzyme-linked immunosorbent assays(Vector-Best JSC,Russia;IBL International,Germany)during routine visits between January 2022 and April 2023.RESULTS A complete two-dose MMR course had been administered to 66.3%of IBD patients and 55.9%of JIA patients(P=0.121).By contrast,the three-dose hepatitis B schedule was completed in 74.2%of IBD and 100%of JIA patients(P<0.001).Protective level of anti-vaccine antibodies against measles(47.7%vs 57.7%;P=0.168);mumps(75.3%vs 80.0%;P=0.366);rubella(74.4%vs 98.2%;P<0.0001);and hepatitis B(44.8%vs 50.0%;P=0.514)were detected in IBD and JIA patients,respectively.CONCLUSION Patients with IBD and JIA demonstrated different vaccination coverage patterns and levels of anti-vaccine antibodies.Routine baseline serology and timely booster vaccination should be implemented for all pediatric patients receiving chronic immunosuppression.展开更多
The technology behind vaccine development varies significantly from one vaccine to another depending on the time when the vaccine was first developed. Over the years, the vaccine innovation time has significantly shor...The technology behind vaccine development varies significantly from one vaccine to another depending on the time when the vaccine was first developed. Over the years, the vaccine innovation time has significantly shortened with the advancement of knowledge in the fields of molecular and cell biology, and discoveries in the field of biotechnology. The first vaccines created were tested in a kind of trial-and-error approach which sometimes had deadly side effects. These vaccines used either living, weakened, or completely dead pathogens. The use of whole pathogen vaccines was seen to be time consuming and unpredictable because even though it would cause an immune response, it could vary from person to person, and always had the risk of pathogens returning to virulence causing sometimes fatal outcomes. The next major technology used to create vaccines was subunit vaccines which utilize purified antigens inactivated through various methods. This technology is quite prevalent among the vaccines that are currently in circulation, making them quite effective, and free from fatal side effects. The viral vector vaccine technology has been around for a few decades and utilizes knowledge of molecular genetics to the greatest extent. It uses intermediate vectors to deliver genetic instructions to trigger an immune response within the subject body. The introduction of nucleic acid vaccines is the newest technology and has come to a great deal of attention during the SARS-CoV-2 immunization efforts. The technology primarily utilizes the delivery of genetic information using messenger ribonucleic acid (mRNA) to create characteristic pathogen-specific proteins that in turn generate an immune response in the recipients.展开更多
文摘Background:Despite highly effective vaccines against SARS-CoV-2,COVID-19 vaccine hesitancy persisted in some populations in England during the pandemic,with rates and motivations for hesitancy varying by demographic group.Addressing the drivers of vaccine hesitancy through targeted interventions in hesitant groups is a public health priority for better and more rapid control of disease spread.We aimed to characterise the determinants and subtypes of vaccine hesitancy and identify more persistent forms of hesitancy via analysis of vaccine uptake in a large cross-sectional cohort with linked National Health Service(NHS)data.
基金the National Natural Science Foundation of China(82573571)the Shanghai 2025 Basic Research Plan Natural Science Foundation(25ZR1401393)the First Batch of Open Topics of the Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices(2025QN13)。
文摘The global burden of bacterial infections,exacerbated by antimicrobial resistance(AMR),necessitates innovative strategies.Bacterial protein vaccines offer promise by eliciting targeted immunity while circumventing AMR.However,their clinical translation is hindered by their inherently low immunogenicity,often requiring potent adjuvants and advanced delivery systems.Biomembrane nanostructures(e.g.,liposomes,exosomes,and cell membrane-derived nanostructures),characterized by superior biocompatibility,intrinsic targeting ability,and immune-modulating properties,could serve as versatile platforms that potentiate vaccine efficacy by increasing antigen stability,enabling codelivery of immunostimulants,and facilitating targeted delivery to lymphoid tissues/antigen-presenting cells.This intrinsic immunomodulation promotes robust humoral and cellular immune responses to combat bacteria.This review critically reviews(1)key biomembrane nanostructure classes for bacterial protein antigens,(2)design strategies leveraging biomembrane nanostructures to enhance humoral and cellular immune responses,(3)preclinical efficacy against diverse pathogens,and(4)translational challenges and prospects.Biomembrane nanostructure-driven approaches represent a paradigm shift in the development of next-generation bacterial protein vaccines against resistant infections.
文摘Malignant melanoma,characterized by its high metastatic potential and resistance to conventional therapies,presents a major challenge in oncology.This review explores the current status and advancements in tumor vaccines for melanoma,focusing on peptide,DNA/RNA,dendritic cell,tumor cell,and neoantigen-based vaccines.Despite promising results,significant challenges remain,including the immunosuppressive tumor microenvironment,patient heterogeneity,and the need for more effective antigen presentation.Recent strategies,such as combining vaccines with immune checkpoint inhibitors(ICIs),aim to counteract immune evasion and enhance T cell responses.Emerging approaches,including personalized neoantigen vaccines and the use of self-amplifying RNA platforms,hold promise for overcoming tumor heterogeneity and improving vaccine efficacy.Additionally,optimizing vaccine delivery systems through nanotechnology and genetic modifications is essential for increasing stability and scalability.This review highlights the potential of these innovative strategies to address current limitations,with a focus on how future research can refine and combine these approaches to improve melanoma treatment outcomes.
基金funded by Medical and Health Science and Technology Project of Zhejiang province(Grant number:2023KY633).
文摘Objective:To evaluate the cost-effectiveness of annual trivalent inactivated influenza vaccine(IIV3)under the context of Zhejiang province.Methods:A state transition simulation model was constructed to estimate the health and economic outcomes of IIV3 vaccination program compared to no vaccination for hypothetical cohorts of Zhejiang province stratified by age and risk status.Model input parameters were chosen based on published literatures and expert advices.The analysis used societal perspectives and a one-year time horizon,and permanent outcomes were also included.The primary outcome was the incremental cost-effectiveness ratio(ICER),with expression of US dollars per quality adjusted life years(QALYs)gained.Results:In subgroups not at high risk for influenza-related complications(non-high risk subgroup),ICER ranged from $6268/QALY(for adults aged 50-64 years)to $11260/QALY(for children aged from 6 months to 4 years).In subgroups at high risk for influenza-related complications(high risk subgroup),ICER ranged from cost-saving(adults aged≥65 years)to $5260/QALY(for children aged from 6 months to 4 years).ICER were most sensitive to changes in probability of influenza illness,cost of hospitalization,and probability of death for adults aged 18-49 years with non-high risk status.Conclusions:ICERs of annual influenza vaccination varied by age and risk status but were less than the Gross Domestic Product(GDP)per capita of Zhejiang province($17745 in 2023),which remained cost-effective for all-age and different risk status groups from a societal perspective.
文摘BACKGROUND Patients with inflammatory bowel diseases(IBD)often miss the scheduled vaccines and have a higher risk of infection susceptibility,including vaccineprevented diseases.AIM To evaluate the vaccine coverage and levels of the post-vaccine antibodies against measles,mumps,rubella,and hepatitis B in children with IBD.METHODS Total 98 patients:46 females(47.2%)and 52 males(52.8%)with IBD(Crohn’s disease-75%and ulcerative colitis-25%)with disease onset age-11.0(6.0;14.0)years whom clinical data,vaccination status and levels of the postvaccination antibodies(IgG)for measles,rubella,mumps,hepatitis B,measured with ELISA were prospectively evaluated.The control group consisted of 88 healthy peers from the biobank data.RESULTS Patients with IBD had lower levels of measles,rubella,and hepatitis B,except mumps,compared to controls.Incomplete vaccination/non-protective titer of the antibodies against measles,mumps rubella,and hepatitis B had 33(33.7%)/52.3%,21(21.4%)/50.4%,26(25.8)/25.6%and 26(25.8%)/55.2%,respectively.Patients with incomplete vaccination had a lower age at the diagnosis for all vaccines.The age of the IBD diagnosis≤6 years was the predictor of incomplete vaccination for measles[odds ratio(OR)=4.6,P=0.001],mumps(OR=5.0,P=0.001),rubella(OR=5.4,P=0.0005)and hepatitis B(OR=5.4,P=0.0005)and corticosteroid treatment for measles(OR=2.2,P=0.074)and mumps(OR=3.0,P=0.047)vaccines.Incomplete vaccination was the predictor of nonprotective titer of antibodies against rubella(OR=6.8,95%CI:2.3-19.9,P=0.0002)/mumps(OR=7.0,95%CI:2.4-20.8;P=0.0002).CONCLUSION Patients with IBD had low vaccine coverage and lower levels of anti-vaccine antibodies against measles,rubella,and hepatitis B.Nearly half of the IBD patients require revaccination.
基金upported by the Major Project of Guangzhou National Laboratory(GZNL2024A01002)National Key Plan for Scientific Research and Development of China(2022YFC2303802)+1 种基金National Natural Science Foundation of China(32170651&32370700)Hunan Provincial Natural Science Foundation of China(2024JJ2015).
文摘Dear Editor,Influenza viruses cause significant mortality and morbidity in humans.Vaccination is currently the most effective way to combat the virus(Perofsky and Nelson,2020).Unfortunately,the influenza virus frequently changes its antigenicity through rapid mutations,leading to decreased vaccine efficacy or even failure.To improve vaccine effectiveness,it is necessary to monitor antigenic variation and update vaccine strains when significant antigenic variation occurs(Perofsky and Nelson,2020;Malik et al.,2024).
基金supported by the National Key Research and Development Program of China(2021YFC2301700)the Natural Science Foundation of Heilongjiang Province,China(YQ2022C040)。
文摘Minks are highly susceptible to SARS-CoV-2,and have transmitted SARS-CoV-2 to humans.Oral immunization is one of the most promising strategies to prevent SARS-CoV-2 infection and transmission in minks.Here,we generated 3 recombinant rabies viruses(RABV),rERAG_(333E)/S6P,rERAG_(333E)/DS6P and rERAG_(333E)/BA2S6P,expressing the prefusion-stabilized SARS-CoV-2 spike protein of wild-type(S6P),δ(DS6P)or BA.2(BA2S6P)strain based on an oral rabies vaccine candidate(rERAG_(333E)).Oral or inactivated immunization of the 3 RABVs monovalent or trivalent were safe,and induced robust RABV neutralizing antibody and cross-antibody responses against the three SARS-CoV-2 in mice and minks.The challenge tests showed that 2 doses of rERAG_(333E)-S6P as an oral or inactivated vaccine completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts,and largely prevented viral replication and lung damage caused by wild-type SARS-CoV-2infection in minks.Notably,we also confirmed that 2 doses of rERAG_(333E)-S6P as an oral or inactivated vaccine can largely protect minks against wild-type SARS-CoV-2 transmission via respiratory droplets.Our findings suggest that rERAG_(333E)-based COVID-19 vaccines appear to be suitable oral candidates to protect minks from SARS-CoV-2infection and transmission,and may serve as inactivated vaccines for further investigation in humans.
文摘Most vaccines get injected into muscle,swallowed by mouth,or squirted into the nose.But in a clinical study reported in January 2025 in Nature Medicine[1],researchers in the Netherlands used a less conventional method to deliver an investigational vaccine:mosquito bites.The mosquitoes carried malaria-causing Plasmod-ium falciparum parasites that had been genetically engineered to trigger a productive immune response without making people sick.Nine of ten study participants who each,in a single session,with-stood 50 bites from this laboratory strain of mosquitoes,success-fully fended off infection when challenged with infective malaria parasites six weeks later.
基金supported by The National Key Research and Development Program(Grant No.2024YFA0917200)University of Science and Technology of China(Grant No.2024YCHX07)Chinese Academy of Sciences(Grant No.CX2110240028).
文摘Background:Vaccine hesitancy remains a pressing global challenge,impacting the acceptance and distribution of both long-established and newly developed vaccines.This paper investigates the multifaceted nature of vaccine hesitancy,focusing on the development of the measles vaccine as a historical case study,while drawing comparisons to the coronavirus disease 2019(COVID-19)pandemic.Methods:The study employs a historical and comparative approach to analyze vaccine hesitancy.It examines how technological advances,public policy,and communication strategies have influenced vaccine acceptance.Key lessons from the development of the measles vaccine are compared with challenges encountered during the rapid development and deployment of COVID-19 vaccines.Results:Both historical and contemporary examples reveal commonalities and differences in addressing vaccine hesitancy.While the measles vaccine demonstrated the importance of long-term safety evaluations and public trust-building,the COVID-19 vaccine highlighted the challenges of rapid development timelines and combating misinformation in a digital age.The findings underscore the necessity of transparent communication,equitable access,and proactive engagement in overcoming hesitancy.Conclusion:Understanding the historical and contemporary dynamics of vaccine hesitancy is crucial for promoting public trust and equitable vaccination in an evolving global health landscape.Effective strategies,combining historical lessons with modern innovations,can address public concerns and enhance vaccine acceptance.
基金Supported by Riset Unggulan of Institut Teknologi Bandung,No.125/IT1.B07.1/SPP-DRI/Ⅲ/2025.
文摘Current treatments for chronic hepatitis B(CHB)are lifelong,often accompanied by side effects and the risk of drug resistance,highlighting the urgent need for alternative therapies such as therapeutic vaccines.However,challenges such as selecting appropriate antigens and addressing multiple hepatitis B virus(HBV)genotypes hinder the development of these vaccines.One approach to overcoming these challenges is reverse vaccinology(RV)combined with immunoinformatics.RV uses computational methods to identify antigens from pathogen genetic information,including genomic and proteomic data.These methods have helped researchers identify conserved epitopes across bacterial strains or viral species,including multiple HBV genotypes.Computational tools,such as epitope mapping algorithms,molecular docking analysis,molecular dynamics simulations,and immune response simulations,enable key epitope identification,predict vaccine candidates'binding potential to immune cell receptors,and forecast the immune response.Together,these approaches streamline therapeutic vaccine design for CHB,making it faster,more cost-effective,and accurate.This review aims to explore the potential role of RV and immunoinformatics in advancing therapeutic vaccine design for CHB.
文摘Tuberculosis(TB)remains a critical global health challenge,with 10.8 million new cases and over 1.25 million deaths reported annually,disproportionately affecting low-income regions.Despite its use,the Bacillus Calmette-Guérin(BCG)vaccine provides limited protection against adult pulmonary TB,necessitating novel solutions.The messenger RNA(mRNA)vaccine technology,proven effective in combating coronavirus disease 2019,offers significant promise for TB prevention.These vaccines elicit robust immune responses by encoding antigens that stimulate humoral and cell-mediated immunity,essential for combating mycobacterium TB.Unlike traditional methods,mRNA vaccines are highly adaptable,scalable,and capable of targeting emerging strains.Preclinical studies highlight the enhanced efficacy of mRNA TB vaccines over BCG,demonstrating their ability to reduce bacterial burdens and generate memory T-cell responses critical for long-term protection.However,challenges persist,including mRNA instability,cold-chain storage needs,and mycobacterium’s complex immune evasion strategies.Innovative solutions,such as lipid nanoparticle delivery systems and selfamplifying mRNA platforms,are being developed to address these barriers.The initiation of clinical trials,notably BioNTech’s BNT164,marks a pivotal advancement in TB vaccine development.These trials focus on safety,immuno genicity,and efficacy,particularly in regions with high TB prevalence.While logistical and financial hurdles remain,mRNA vaccines hold transformative potential to bridge critical gaps in TB prevention.Their adaptability extends to tackling co-infections like human immunodeficiency virus,further amplifying their impact on global health.By integrating mRNA vaccines into existing TB control strategies,these advancements could revolutionize prevention efforts,especially in regions where current solutions fall short.Continued innovation and investment are crucial to harnessing the full potential of mRNA vaccines,positioning them as a cornerstone in the fight against TB and its global eradication.
文摘Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently followed by a significant rise in domestic infections commencing from June 2023.This alarming trend has escalated the likelihood of localized outbreaks and covert transmission,posing a heightened risk to public health.Notably,the United States,many European countries,and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure,based on their cross-protection efficacy.In recent years,virology research has broadened its scope to include investigations into various novel vaccine approaches,such as nucleic acid-based vaccines,protein subunit vaccines,and epitope peptide vaccines,and other related methodologies.This review offers a thorough examination of the current global landscape of Mpox prevalence,delves into the advancements in Mpox vaccine development,and highlights the progress achieved in Mpox vaccine research,serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.
基金the Study on Vaccine Application Evaluation Strategies and Capacity Building (INV-006373)the National Key R&D Program of China(2024YFC2310604)
文摘Objective The objective of our study was to evaluate the vaccine effectiveness(VE)of the pentavalent rotavirus vaccine(RV5)among<5-year-old children in three provinces of China during 2020-2024 via a propensity score-matched test-negative case-control study.Methods Electronic health records and immunization information systems were used to obtain data on acute gastroenteritis(AGE)cases tested for rotavirus(RV)infection.RV-positive cases were propensity score matched with RV-negative controls for age,visit month,and province.Results The study included 27,472 children with AGE aged 8 weeks to 4 years at the time of AGE diagnosis;7.98%(2,192)were RV-positive.The VE(95%confidence interval,CI)of 1-2 and 3 doses of RV5 against any medically attended RV infection(inpatient or outpatient)was 57.6%(39.8%,70.2%)and 67.2%(60.3%,72.9%),respectively.Among children who received the 3rd dose before turning 5 months of age,3-dose VE decreased from 70.4%(53.9%,81.1%)(<5 months since the 3rd dose)to 63.0%(49.1%,73.0%)(≥1 year since the 3rd dose).The three-dose VE rate was 69.4%(41.3%,84.0%)for RVGE hospitalization and 57.5%(38.9%,70.5%)for outpatient-only medically attended RVGE.Conclusion Three-dose RV5 VE against rotavirus gastroenteritis(RVGE)in children aged<5 years was higher than 1-2-dose VE.Three-dose VE decreased with time since the 3rd dose in children who received the 3rd dose before turning five months of age,but remained above 60%for at least one year.VE was higher for RVGE hospitalizations than for medically attended outpatient visits.
文摘The original version of Figure 2 contained the following inaccuracies:Rotarix was incorrectly shown as a 3-dose vaccine instead of a 2-dose vaccine;RotaTeq and Rotasiil were incorrectly shown as 2-dose vaccines instead of 3-dose vaccines;Polyvac was incorrectly shown as a 3-dose vaccine instead of a 2-dose regimen;and the LLR vaccine should have been indicated as a single primary dose followed by annual boosters between 2 months and 3 years of age.
文摘Imagine a future where a single vaccine could protect you from a multitude of influenza strains,offering broad immunity with minimal risk.This vision is now closer to reality,thanks to a recent study that harnesses the power of cellular proteins to create a new generation of live attenuated vaccines that outsmart flu’s relentless mutations.
文摘BACKGROUND Child vaccination plays a great role in preventing infectious diseases in children.While Ethiopia has emphasized child vaccination,its effectiveness largely depends on efficient communication between health practitioners and mothers/caregivers.Thus,sufficient communication contributes to promoting child immunization and in turn improving child health.AIM To examine child vaccine communication practices and strategies as well as their relationship with sociodemographic characteristics of respondents in the Amhara region of Ethiopia.METHODS A quantitative cross-sectional survey was conducted using a pretested Likert scale questionnaire and distributed to 123 health workers in primary healthcare centers between April 2024 and June 2024.The data were analyzed using both descriptive and inferential statistics.RESULTS The results indicated that the most common vaccine communication activities included education and communication(mean score=24.1),vaccine data registration(mean score=8.86),and information exchange(mean score=8.3).A significant correlation was found between the implementation of interpersonal health communication principles and immunization communication training(F=341.756,P=0.000,P<0.05).However,no significant correlations were observed between age,education,work experience,and vaccine communication practices.Additionally,the study found that the application of interpersonal communication principles was associated with the perceived relevance of immunization communication(F=27.790,P=0.000,P<0.05).CONCLUSION Based on the findings the study concluded that communication practice in promoting child immunization is insufficient.To enhance vaccine acceptance,continuous immunization communication training for health workers is recommended.
基金supported by the National Natural Science Foundation of China(82341042 and 32270993)the PhD program of the Interdisciplinary Research Center,Sun Yat-sen University.
文摘Tumor initiation and progression are highly intricate biolog-ical processes,and mutation-driven tumorigenesis is a pri-mary underlying cause.Personalized cancer vaccines have been developed to exploit these specific mutations,particu-larly in the form of tumor neoantigens,to induce immune responses,particularly the activation of CD8+T cells,which can attack malignant cells.Since tumor mutations result in protein sequence alterations distinct from those in normal tissues,therapies that precisely target these alterations could,in principle,confer effective tumor control while minimizing off-target effects.
基金District of Medical and Health Research Project(2023JD212)Shenzhen Bao’an District of Traditional Chinese Medicine Clinical Research Project(2023ZYYLCZX-12)+2 种基金Shenzhen“Medical and Health Three Projects”Project Grant(SZZYSM 202106003)Weifang Health Committee Scientific Research Project(wfwsjk-2023-170)Shenzhen Pingshan District of Health System Research Project(2024334).
文摘Bacckground:Based on the 3C model,this study explores the current situation of HPV vaccine hesitancy among women of childbearing age and the factors influencing vaccine hesitancy.Methods:Based on the free cervical cancer screening project in Baoan District,this study designed a questionnaire under the framework of vaccine hesitation 3C theory and carried out a self-filling electronic questionnaire survey among women of childbearing age.Results:The rate of HPV vaccination awareness among women of childbearing age in Bao’an District was 93.25%.HPV vaccine acceptance reached 71.55%,and 24.59%of the survey respondents experienced HPV vaccine hesitation,a high percentage of whom were hesitant.The influencing factors of HPV vaccine hesitation among women of childbearing age were perceived necessity of HPV vaccination(0.482),no one around them receiving the HPV vaccine(0.411),perception of the price of the vaccine(0.354),degree of trust in the safety of the vaccine(0.223),and degree of concern about the HPV vaccine(0.153).Conclusion:The 3C model can be used for the study of HPV vaccine hesitancy.Strengthening the publicity of HPV vaccination and improving women’s knowledge of the HPV vaccine can reduce their hesitation toward HPV vaccination.
文摘BACKGROUND Children with juvenile idiopathic arthritis(JIA)and inflammatory bowel disease(IBD)face an elevated risk of severe infection owing to their diseases and the immunosuppressive treatment for disease control.AIM To compare scheduled vaccination coverage and the levels of post-vaccine antibodies against measles,mumps,rubella(MMR)and hepatitis B in pediatric patients with IBD and JIA.METHODS A comparative cohort study included 97 patients with IBD and 170 patients with JIA.Vaccination history was obtained from medical records,while post-vaccination immunity was assessed prospectively by measuring specific IgG antibody titers using enzyme-linked immunosorbent assays(Vector-Best JSC,Russia;IBL International,Germany)during routine visits between January 2022 and April 2023.RESULTS A complete two-dose MMR course had been administered to 66.3%of IBD patients and 55.9%of JIA patients(P=0.121).By contrast,the three-dose hepatitis B schedule was completed in 74.2%of IBD and 100%of JIA patients(P<0.001).Protective level of anti-vaccine antibodies against measles(47.7%vs 57.7%;P=0.168);mumps(75.3%vs 80.0%;P=0.366);rubella(74.4%vs 98.2%;P<0.0001);and hepatitis B(44.8%vs 50.0%;P=0.514)were detected in IBD and JIA patients,respectively.CONCLUSION Patients with IBD and JIA demonstrated different vaccination coverage patterns and levels of anti-vaccine antibodies.Routine baseline serology and timely booster vaccination should be implemented for all pediatric patients receiving chronic immunosuppression.
文摘The technology behind vaccine development varies significantly from one vaccine to another depending on the time when the vaccine was first developed. Over the years, the vaccine innovation time has significantly shortened with the advancement of knowledge in the fields of molecular and cell biology, and discoveries in the field of biotechnology. The first vaccines created were tested in a kind of trial-and-error approach which sometimes had deadly side effects. These vaccines used either living, weakened, or completely dead pathogens. The use of whole pathogen vaccines was seen to be time consuming and unpredictable because even though it would cause an immune response, it could vary from person to person, and always had the risk of pathogens returning to virulence causing sometimes fatal outcomes. The next major technology used to create vaccines was subunit vaccines which utilize purified antigens inactivated through various methods. This technology is quite prevalent among the vaccines that are currently in circulation, making them quite effective, and free from fatal side effects. The viral vector vaccine technology has been around for a few decades and utilizes knowledge of molecular genetics to the greatest extent. It uses intermediate vectors to deliver genetic instructions to trigger an immune response within the subject body. The introduction of nucleic acid vaccines is the newest technology and has come to a great deal of attention during the SARS-CoV-2 immunization efforts. The technology primarily utilizes the delivery of genetic information using messenger ribonucleic acid (mRNA) to create characteristic pathogen-specific proteins that in turn generate an immune response in the recipients.
